Given the fact that PC is the third leading cause of cancer-associated death in men and that the FDA has now approved radioligand therapy for the treatment of progressive PSMA-positive metastatic castration-resistant PC, molecular PSMA imaging is becoming more and more important [21, 26, 27]. This evidence concerns the gene FOLH1 and pachyonychia congenita.